Efficient vaccine against pandemic influenza: combining DNA vaccination and targeted delivery to MHC class II molecules.
There are two major limitations to vaccine preparedness in the event of devastating influenza pandemics: the time needed to generate a vaccine and rapid generation of sufficient amounts. DNA vaccination could represent a solution to these problems, but efficacy needs to be enhanced. In a separate line of research, it has been established that targeting of vaccine molecules to antigen-presenting cells enhances immune responses. We have combined the two principles by constructing DNA vaccines that encode bivalent fusion proteins; these target hemagglutinin to MHC class II molecules on antigen-presenting cells. Such DNA vaccines rapidly induce hemagglutinin-specific antibodies and T cell responses in immunized mice. Responses are long-lasting and protect mice against challenge with influenza virus. In a pandemic situation, targeted DNA vaccines could be produced and tested within a month. The novel DNA vaccines could represent a solution to pandemic preparedness in the advent of novel influenza pandemics.
['Grødeland|Gunnveig|G|', 'Bogen|Bjarne|B|']
D000818:Animals D000914:Antibodies, Viral D000956:Antigens, Viral D055808:Drug Discovery D019267:Hemagglutinin Glycoproteins, Influenza Virus D000949:Histocompatibility Antigens Class II D006801:Humans D007252:Influenza Vaccines D007251:Influenza, Human D058873:Pandemics D013601:T-Lymphocytes D013678:Technology, Pharmaceutical D014611:Vaccination D019444:Vaccines, DNA
vaccine influenza DNA vaccine antibodies APC targeting MHC II molecules